Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587769 · ClinicalTrials.gov registry record · Phase 3
Chantix & Bupropion for Smoking Cessation
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
NCT00587769: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT00587769 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587769, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
Study Summary
The overarching goal of this line of research is to increase smoking abstinence rates using a combination of existing pharmacotherapies. The aim of the current study is to assess the safety and compliance as well as obtain preliminary estimates of efficacy and effect on craving and nicotine withdrawal of combination therapy with bupropion SR and varenicline. We will compare the efficacy estimates in this study with historical smoking abstinence rates with varenicline. To accomplish our aims, we will enroll 38 cigarette smokers in an open-label, phase II clinical trial.
Interventions
- DRUG Bupropion SR & Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587769
The ClinicalTrials.gov registry entry for NCT00587769 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion SR & Varenicline is the first listed.
NCT00587769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587769 about?
NCT00587769 is a clinical study titled "Chantix & Bupropion for Smoking Cessation". The overarching goal of this line of research is to increase smoking abstinence rates using a combination of existing pharmacotherapies. The aim of the current study is to assess the safety and compliance as well as obtain preliminary estimates of efficacy and effect on craving and nicotine withdraw...
What is the current status of trial NCT00587769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2007-07. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00587769?
The interventions under investigation include: Bupropion SR & Varenicline (DRUG).
Who is sponsoring clinical trial NCT00587769?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.